Sol-Gel Technologies Ltd
NASDAQ:SLGL 2:46:28 PM EDT
Products
Sol Gel Acquires Patidegib
Published: 01/27/2023 12:19 GMT
Sol-Gel Technologies Ltd (SLGL) - Sol Gel Technologies Ltd - Phase 3 Study Expected to Initiate in Second Half of 2023, With Results Expected by End of 2025.
Sol-gel Acquires Patidegib, a Phase 3, FDA-breakthrough-designated Orphan Product Candidate to Pursue Potential Market of Over $300 Million.
Sol-gel Acquires Patidegib, a Phase 3, FDA-breakthrough-designated Orphan Product Candidate to Pursue Potential Market of Over $300 Million.
Sol Gel Technologies Ltd - Phase 3 Study Expected to Initiate in Second Half of 2023, With Results Expected by End of 2025.
Sol Gel Technologies Ltd - Estimate That Sgt-610, If Approved by FDA, Has Potential to Generate, at Peak, Annual Net Sales in Excess of $300 Million.
Sol Gel Technologies - Will Pay Pellepharm Upfront Payment of $4.7 Million and Total Development and NDA Acceptance Milestones of Up to $6.0 Million.
Sol Gel Technologies - Will Pay Pellepharm Up to $64.0 Million in Commercial Milestones As Well As Single Digit Royalties.
Sol-gel Acquires Patidegib, a Phase 3, FDA-breakthrough-designated Orphan Product Candidate to Pursue Potential Market of Over $300 Million.
Sol-gel Acquires Patidegib, a Phase 3, FDA-breakthrough-designated Orphan Product Candidate to Pursue Potential Market of Over $300 Million.
Sol Gel Technologies Ltd - Phase 3 Study Expected to Initiate in Second Half of 2023, With Results Expected by End of 2025.
Sol Gel Technologies Ltd - Estimate That Sgt-610, If Approved by FDA, Has Potential to Generate, at Peak, Annual Net Sales in Excess of $300 Million.
Sol Gel Technologies - Will Pay Pellepharm Upfront Payment of $4.7 Million and Total Development and NDA Acceptance Milestones of Up to $6.0 Million.
Sol Gel Technologies - Will Pay Pellepharm Up to $64.0 Million in Commercial Milestones As Well As Single Digit Royalties.